Reported about 7 hours ago
Biogen anticipates lower profits for 2025 due to intense competition for multiple sclerosis treatments and a strong dollar, predicting a decline in revenue by mid-single digits compared to 2024. With shares down and concerns over slow launches of key drugs, CEO Christopher Viehbacher highlights a restructuring plan focused on future growth. Expected adjusted profit per share is between $15.25 and $16.25, falling short of analyst expectations.
Source: YAHOO